Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $29M Series A. Acquired ARMMs vesicular delivery tech (Mar 2025). Delivers mRNA cocktails that transiently reprogram aged cells to youthful epigenetic states without altering DNA.
Turn Biotechnologies is a longevity company using modified mRNA cocktails to transiently reprogram aged cells back toward a youthful epigenetic state — without permanently altering DNA sequences. The company has raised $29 million in Series A financing and acquired ARMMs (Arrestin Domain-Containing Protein 1 Mediated Microvesicle) technology in March 2025 to significantly upgrade the delivery capability of its mRNA reprogramming platform.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.